Cell Tracking in Cancer Immunotherapy

Autor: Justine Perrin, Marisa Capitao, Marie Mougin-Degraef, François Guérard, Alain Faivre-Chauvet, Latifa Rbah-Vidal, Joëlle Gaschet, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel, Jacques Barbet

Publikováno v: Frontiers in Medicine, Vol 7 (2020)

The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new targets and new therapeutic tools. Since different stages

Externí odkaz: https://doaj.org/article/917a62510146415d8739dae10daa49e9

Pretargeting for imaging and therapy in oncological nuclear medicine

Autor: Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Jacques Barbet

Publikováno v: EJNMMI Radiopharmacy and Chemistry, Vol 2, Iss 1, Pp 1-14 (2017)

Abstract Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval

Externí odkaz: https://doaj.org/article/d8551b493b254c6699eda614f4cadf5d

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches

Autor: Caroline Bodet-Milin, Clément Bailly, Yann Touchefeu, Eric Frampas, Mickael Bourgeois, Aurore Rauscher, Franck Lacoeuille, Delphine Drui, Nicolas Arlicot, David M. Goldenberg, Alain Faivre-Chauvet, Jacques Barbet, Caroline Rousseau, Françoise Kraeber-Bodéré

Publikováno v: Frontiers in Medicine, Vol 6 (2019)

Monoclonal antibody (mAb)-based therapies have experienced considerable growth in cancer management. When labeled with radionuclides, mAbs also represent promising probes for imaging or theranostic approaches. Initially, mAbs have been radiolabeled w

Externí odkaz: https://doaj.org/article/84f344d109794441b254c9b9cb7783b9

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety

Autor: John O. Prior, Silvano Gnesin, Séverine Marionneau-Lambot, Jacques Barbet, David Viertl, Niklaus Schaefer, Judith Anna Delage, Steven M. Dunn, Mickaël Bourgeois, Julie K. Fierle, Sébastien Gouard, Michel Chérel, Patricia Le Saëc, Alain Faivre-Chauvet

Publikováno v: Cancers
Cancers, 2021, 13 (23), pp.5936. ⟨10.3390/cancers13235936⟩
Cancers; Volume 13; Issue 23; Pages: 5936
Cancers, Vol 13, Iss 5936, p 5936 (2021)
Cancers, vol. 13, no. 23, pp. 5936

Simple Summary The prevalence of TEM-1 in the vasculature and the stroma of solid tumors and in malignant cells of sarcomas suggests that targeting TEM-1 could have therapeutic benefit. In this context, an anti-TEM-1 companion diagnostic may assist i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94e900dbcc10680c6aa643076246719
https://pubmed.ncbi.nlm.nih.gov/34885044

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.

Autor: Mickaël Terme, Mylène Dorvillius, Denis Cochonneau, Tanguy Chaumette, Wenhua Xiao, Mitchell B Diccianni, Jacques Barbet, Alice L Yu, François Paris, Linda S Sorkin, Stéphane Birklé

Publikováno v: PLoS ONE, Vol 9, Iss 2, p e87210 (2014)

Anti-GD2 antibody is a proven therapy for GD2-positive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies. Pain, however, can limit immunotherapy with anti-GD2 therapeuti

Externí odkaz: https://doaj.org/article/3b49ad6202ac4463bff6f98234611e69